PARP1 and ovarian cancer: The combination of other therapeutic agents (such as antiangiogenic agents) with PARP inhibitors may offer a strategy to increase the sensitivity of BRAC-proficient ovarian cancers to PARP inhibitors and to improve their therapeutic response.